



Star specialty care	Discount Pharmacy		Psoriasis Call: (877) 883-1392 Fax: (256) 429-2221			
Patient Inform Address:	Action:         Name:					
Prescriber Info	prmation: Name: Phone:	Address:		City:	State:	
	Medical Necessity (Please Attach All Medi					
LFT: ALT:	s: ICD-10: AST: Date: O Chest O Arms O Hands O Nails O Bac	_ Assessment: O Mode	erate OMod to Severe	O Severe% BSA Af		
Serious or activ Hep B ruled ou Does patient h Injection Trainin O To be Adminis O Patient Traine Support	king methotrexate? O Yes O Nove infection present? O Yes O Nove infection present? O Yes O Nove to retreatment started? O Yes O Nove latex allergy? O Yes O Nove I O Pharmacist to Provide Training tered by a Healthcare Provider d in MD Office O Manufacturer Nurse Y: O Patient's Home O Physician's Office	Prior Failed Treatme O Topicals O Methotrexate O Oral Meds O Biologics O UVA O UVB O Others O Pharmacy to Coord		Length of Treatment		
Prescription In						
Medication  O Cimzia	Dosage & Strength  ○200mg/ml Prefilled Syringe  ○200mg Lyophilized Powder Vial	O Induction Dinitially and	g SC every other week ose: (Weight <90kg) Inject at weeks 2 and 4 e Dose: (Weight <90kg) Inj	400mg SC every other week ect 200mg SC every other	Qty	Ref
○ Cosentyx	○150mg/ml Sensoready Pen ○150mg/ml Prefilled Syringe ○150mg/ml Lyophilized Powder Vial	OInduction D	ose: Inject 150mg SC at weose: Inject 300mg SC at weoe Dose: Inject 150mg SC ev	eks 0, 1, 2, 3, and 4	5 10 1	0

Medication	Dosage & Strength	Direction	Qty	Ref
O Cimzia	○200mg/ml Prefilled Syringe	OInject 400mg SC every other week		
		O Induction Dose: (Weight <90kg) Inject 400mg SC every other week		
	○200mg Lyophilized Powder Vial	initially and at weeks 2 and 4		
		O Maintenance Dose: (Weight <90kg) Inject 200mg SC every other		
		week		
○ Cosentyx	○150mg/ml Sensoready Pen	OInduction Dose: Inject 150mg SC at weeks 0, 1, 2, 3, and 4	5	0
	○150mg/ml Prefilled Syringe	OInduction Dose: Inject 300mg SC at weeks 0, 1, 2, 3, and 4	10	0
	○150mg/ml Lyophilized Powder Vial	OMaintenance Dose: Inject 150mg SC every four weeks	1	
	O 300mg/2mL Unoready Pen	OMaintenance Dose: Inject 300mg SC every four weeks	2	
O Enbrel	○ 50mg/ml Sureclick Autoinjector	OInduction Dose: Inject 50mg SC twice a week	8	2
		(3-4 days apart) for 3 months, then start maintenance dosing		
		Maintenance: Inject 50mg SC once a week	4	
	○ 50mg/ml Prefilled Syringe	Pediatric Patients: To achieve pediatric doses other than		
	O 25mg Lyophilized Powder Multiple Dose Vial	50mg or 25mg, use reconstituted Enbrel lyophilized powder		
	O Other:	O> 138lbs or more: Inject 50mg weekly	4	
		O < 138lbs: Inject 0.8mg/kg weekly	-	
		Other:		
O Humira	OPsoriasis Starter Package	Olnduction Dose: Inject 80mg SC on day 1, then 40mg SC	3	0
Orianina	080mg/0.8ml Pen	on day 8, then 40mg SC every other week		ľ
	O40mg/0.4ml Pen	Maintenance: Inject 40mg SC every other week	2	
	○40mg/0.4ml Prefilled Syringe	Other:	-	
	O40mg/0.8ml Pen	Ges		
	O40mg/0.8ml Prefilled Syringe			
	OHidradenitis Suppurativa Starter Package	○Induction Dose:	3	0
	80mg/0.8ml Pen	Olnject two 80mg pens SC on day 1, then one 80mg pen SC on day 15		
	3, 1	Olnject one 80mg pen SC on day 1, one 80mg pen on day 2, then one		
		80mg pen on day 15		
	○ 40mg/0.4ml Pen	Maintenance: Inject 40mg SC on day 29 and every week thereafter	4	
	○ 40mg/0.4ml Prefilled Syringe			
	O 40mg/0.8ml Pen	Patient has signed HUMIRA Complete form		
	O 40mg/0.8ml Prefilled Syringe			
O Orencia	O 125mg/ml ClickJectTM Autoinjector	O Inject 125mg SC once a week	4	
	O 125mg/ml Prefilled Syringe			
O Otezla	O Starter Pack (Titration)	Starter Pack: Take one tablet in the morning on day 1, then take one	1	0
		tablet in the morning and one tablet in the evening as directed on the		
		starter pack		
	O 30mg Tablets	Maintenance: Take one 30mg tablet by mouth twice daily	60	
C	0	0		

Prescriber Signature (I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs)								
Signature: _		Signature:	Date:					
	Substitution Permitted	Dispense as Written						
Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this								
program is not a guarantee of prior authorization or of payment.								

Confidentiality Notice: This fax is intended to be delivered only to the named addressee and contains confidential information that may be protected health information under federal and state laws. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please inform the sender immediately if you have received this document in error and then destroy this document immediately.